


Prevalence of pfhrp2/3 deletions in South Sudan: results of a 10-site survey



Désiré Ndisabiye, Olivier Denis, Pascale Chaillet, Letizia Di Stefano, Erwan Piriou, Constantino Doggale, Jane Cunningham, Valérie Briand, Qin Cheng, Matthew E Coldiron

Conflicts of Interest

All authors declare no competing interests.

Ethics

This study was approved by the South Sudan Ministry of Health Research Ethics Review Board (ERB) (Ref: MOH/RERB/A/32/2023), the Médecins Sans Frontières ERB (Ref: 2310a), and the Australia Departments of Defence and Veterans' Affairs Human Research Ethics Committee (Ref: 518-23).

RDTs purchased by MSF in
2024 > 7 million

Malaria-RDTs



Detect the parasite's antigens in the blood:

- Histidine rich protein 2 (HRP2)**
- Lactate dehydrogenase (LDH)
- Aldolase

Strains with pfhrp2 and pfhrp3 gene deletions are undetectable by HRP2 RDTs




False negative results

WHO recommends that countries with more than 5% of false negative results due to HRP 2/3 deletion, implement non-PfHRP-2 based RDT.

Why do an HRP 2/3 deletion survey in South Sudan?

- High endemicity
- > 97% of cases by *P. falciparum*
- Neighboring countries with documented pfhrp2/3 deletions
- Suspicion of false negative HRP2-mRDT at field level
- Data on South Sudan extremely scarce
- MSF has large operational footprint




Objectives and methodology

Primary objective: Estimate prevalence of pfhrp2/3 deletions

- Cross-sectional survey at 10 sites (5 MSF Operational Centers)
- Done in collaboration with MoH South Sudan, WHO, ADFMIDI
- Patients < 15 years with suspected malaria
- 2 RDTs in parallel: HRP2 and PfpLDH-based
- DBS for molecular testing

Results

Site	samples	HRP2+/ pLDH+	HRP2-/ pLDH+	HRP2+/ pLDH-	HRP2-/ pLDH-
Lankien	190	51	2	18	77
Malakal	200	93	2	19	128
Aweil	184	59	0	22	103
Kajo Keji	183	84	2	9	89
Gomgoi	200	44	0	18	137
Bentiu	196	22	1	3	170
Ulang	201	55	3	25	117
Old Fangak	197	70	1	13	42
Maruwa	199	35	2	6	156
Yei	156	52	1	27	75
Total	1832	565	14	160	1094



Implications

- Prevalence of HRP2/3 deletion causing false negative results = 0.35% (95%CI 0.04-1.24)



HRP2-based RDT still suitable in our sites in South Sudan

- Results considered by NMCP for next order of RDTs
- First report of new generation Pf-pLDH-based mRDT detecting non-P. falciparum species → not encouraging!
- **The study has direct implications for the National Malaria Control Programme and health actors working in South Sudan, it contributes to the global surveillance of HRP 2/3 deletion and aligns with MSF's quality of care goals.**

Thanks to all patients and staff

Ministry of Health
Republic of South Sudan



Ministry of Health of South Sudan
Constantino Doggale



Epicentre
Valérie Briand
Céline Langendorf



ADFMIDI
Qin Cheng
David Smith
Jye Travis
Cielo Pasay

Médecins Sans Frontières

Désiré Ndisabiye
Olivier Denis
Pascale Chaillet
Letizia Di Stefano
Erwan Piriou
Alain Ngoko
Iro Evlampidou
Laura Cremonini



WHO

Jane Cunningham
Andrea Bosman

